Last updated: February 19, 2026
FELDENE, a nonsteroidal anti-inflammatory drug (NSAID) developed by Pfizer, has experienced significant market shifts following patent expiration and the subsequent influx of generic competition. Its primary indication is for the symptomatic treatment of rheumatoid arthritis and osteoarthritis. The drug's active pharmaceutical ingredient is Piroxicam.
What is the Current Patent Status of FELDENE?
FELDENE's compound patent expired globally by the early 2000s. For example, in the United States, the primary compound patent expired in 2002 [1]. While specific formulation or method-of-use patents may have existed or still exist in limited jurisdictions, the core patent protection for Piroxicam has long lapsed. This has allowed for the widespread entry of generic Piroxicam products into the market.
How Has Generic Entry Impacted FELDENE's Market Share and Pricing?
The introduction of generic Piroxicam has led to a substantial decline in brand-name FELDENE's market share. Generic manufacturers can produce Piroxicam at a lower cost, allowing them to offer significantly lower prices. This price differential is a primary driver of physician and patient switching away from the branded product.
- Market Share: Prior to patent expiration, FELDENE held a dominant position in the Piroxicam market. Post-expiration, its market share has been eroded by numerous generic competitors. While precise, up-to-the-minute market share data for specific branded drugs versus their generics is often proprietary, industry analyses consistently show a steep decline in branded NSAID market share after generic entry. For instance, in the NSAID class, generic penetration often exceeds 80-90% within a few years of the first generic launch [2].
- Pricing: The price of generic Piroxicam is typically a fraction of the original FELDENE price. A single-unit average wholesale price (AWP) for branded FELDENE could have ranged from $3 to $6 USD per tablet or capsule in its peak years, depending on dosage and formulation. Generic Piroxicam is commonly available at AWP ranging from $0.10 to $0.50 USD per unit, representing a price reduction of over 90% [3]. This dramatic price compression is a standard outcome of generic competition.
What is the Global Sales Performance of FELDENE?
Global sales performance for branded FELDENE has been in consistent decline since the early 2000s. Pfizer's financial reports would have reflected this decline through reduced reporting of FELDENE as a significant revenue contributor. Specific figures for branded FELDENE sales are no longer prominently disclosed by Pfizer due to its mature status and the dominance of generic alternatives.
However, the market for Piroxicam as a therapeutic agent, encompassing both branded and generic forms, still represents a significant volume of prescriptions, albeit at lower aggregate revenue due to generic pricing. The total global market for Piroxicam (all brands and generics) is estimated to be in the low tens of millions of USD annually, a stark contrast to the hundreds of millions it may have achieved during its patent-protected period [4].
What are the Key Therapeutic Alternatives to FELDENE?
FELDENE (Piroxicam) belongs to the NSAID class. Its primary therapeutic alternatives include other NSAIDs and non-NSAID pain relievers. The selection of an alternative is often based on efficacy, side effect profile, patient history, and cost.
- Other NSAIDs (Non-Selective COX Inhibitors):
- Ibuprofen (e.g., Advil, Motrin)
- Naproxen (e.g., Aleve, Naprosyn)
- Diclofenac (e.g., Voltaren)
- Indomethacin
- COX-2 Selective Inhibitors:
- Celecoxib (e.g., Celebrex)
- Non-NSAID Pain Relievers:
- Acetaminophen (e.g., Tylenol)
The development of selective COX-2 inhibitors and the continued widespread availability of over-the-counter NSAIDs and acetaminophen have also contributed to a more fragmented market, diminishing the relative prominence of older NSAIDs like Piroxicam, even in their generic forms.
What is the Regulatory Landscape for Piroxicam?
Piroxicam is approved by major regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Regulatory actions since its initial approval have primarily focused on safety labeling updates.
- FDA Actions: The FDA has issued updated safety warnings for NSAIDs, including Piroxicam, concerning cardiovascular risks, gastrointestinal bleeding, and renal effects. The most significant warnings relate to the increased risk of heart attack, stroke, and death associated with NSAID use. Prescribing information for Piroxicam now includes boxed warnings detailing these risks [5].
- EMA Actions: The EMA has similarly reviewed and updated the safety profile of Piroxicam, reinforcing warnings about serious gastrointestinal adverse events, cardiovascular risks, and renal toxicity. Restrictions on duration of use and dosage have been recommended in various European countries to mitigate these risks [6].
These updated safety profiles can influence prescribing patterns, with healthcare providers potentially opting for alternatives perceived as having a more favorable risk-benefit ratio, especially for long-term use.
What are the Manufacturing and Supply Chain Considerations for Piroxicam?
The manufacturing of Piroxicam is now largely carried out by generic pharmaceutical companies, primarily in India and China, where cost-effective API production is concentrated.
- API Production: Active Pharmaceutical Ingredient (API) for Piroxicam is manufactured by multiple global suppliers. Key manufacturing hubs include India and China, which offer competitive pricing and established chemical synthesis capabilities.
- Finished Dosage Forms: Formulations of Piroxicam (e.g., capsules, tablets) are produced by numerous generic drug manufacturers in various countries. The ease of synthesis and established manufacturing processes for Piroxicam contribute to the low cost of generic production.
- Supply Chain: The supply chain is robust due to the large number of manufacturers. This reduces the risk of supply disruptions for generic Piroxicam. However, quality control remains paramount, with regulatory bodies conducting inspections to ensure compliance with Good Manufacturing Practices (GMP).
What is the Future Market Outlook for Piroxicam?
The future market outlook for Piroxicam is characterized by continued competition within the generic space and a stable, albeit low-revenue, demand for its therapeutic benefits.
- Generic Dominance: Branded FELDENE will remain a niche product, with the vast majority of Piroxicam prescriptions filled by generics.
- Pricing Pressure: Intense competition among generic manufacturers will maintain downward pressure on prices.
- Therapeutic Niche: Piroxicam will likely retain its place as a treatment option for specific patient populations where its pharmacokinetic profile (e.g., long half-life allowing once-daily dosing) is advantageous, and where cost is a significant factor. However, its use is increasingly tempered by safety concerns and the availability of newer or perceived safer alternatives.
- Regulatory Scrutiny: Ongoing pharmacovigilance and regulatory updates regarding NSAID safety will continue to influence prescribing trends.
The overall market value for Piroxicam is unlikely to see significant growth and will largely be driven by volume rather than price appreciation.
Key Takeaways
- FELDENE's compound patent expired in the early 2000s, leading to widespread generic Piroxicam entry.
- Generic competition has resulted in a dramatic decrease in branded FELDENE market share and a significant reduction in Piroxicam pricing.
- Global sales of branded FELDENE have declined substantially, with the Piroxicam market now primarily driven by generics.
- Numerous NSAIDs and non-NSAID pain relievers serve as therapeutic alternatives to Piroxicam.
- Regulatory bodies have reinforced safety warnings for NSAIDs, including Piroxicam, concerning cardiovascular, gastrointestinal, and renal risks.
- Piroxicam API and finished dosage forms are manufactured globally, with cost-effective production concentrated in Asia.
- The future market for Piroxicam is expected to remain dominated by generics, characterized by low pricing and stable, volume-driven demand.
FAQs
-
What is the primary active ingredient in FELDENE?
The primary active ingredient in FELDENE is Piroxicam.
-
When did the main patent for FELDENE expire?
The main compound patent for FELDENE expired globally by the early 2000s, with the U.S. patent expiring in 2002.
-
How has the price of Piroxicam changed since generic entry?
The price of generic Piroxicam is substantially lower than branded FELDENE, often representing a price reduction of over 90%.
-
What are the main safety concerns associated with Piroxicam?
Key safety concerns include increased risk of cardiovascular events (heart attack, stroke), serious gastrointestinal bleeding, and renal toxicity.
-
Where is Piroxicam API predominantly manufactured?
Active Pharmaceutical Ingredient (API) for Piroxicam is predominantly manufactured in India and China.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Specific patent expiry dates are searchable within the database, though direct links to expired patents are not stable.)
[2] IQVIA Institute for Human Data Science. (2023). The Use of Medicines in the United States: 2023. [Specific report details vary annually; refer to latest IQVIA reports on drug utilization and market trends.]
[3] First Databank, Inc. (as of recent data). Red Book Online: Drug Pricing and Product Information. (Pricing data is proprietary and varies by formulary and acquisition costs. Generic price ranges are derived from industry standard data providers.)
[4] Evaluate Pharma. (Recent Market Analysis Reports). (Proprietary market data and forecasts for therapeutic areas and specific drug classes.)
[5] U.S. Food & Drug Administration. (2015, July 17). FDA Drug Safety Communication: FDA strengthens warning on NSAIDs in connection with heart attack and stroke risk. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-nsaids-connection-heart-attack-and-stroke-risk (General NSAID warnings apply to Piroxicam).
[6] European Medicines Agency. (Various Safety Reviews and Public Assessment Reports). Retrieved from https://www.ema.europa.eu/ (Specific Piroxicam assessments are available via EMA's website.)
